Executive Summary
Across 34 diverse SEC filings labeled under S&P 500 Consumer Staples (though spanning energy, tech, biotech, REITs, media), overarching themes reveal mixed sentiment with robust revenue growth in 9/18 reporting companies averaging +18% YoY (e.g., MongoDB +27%, Helios +17% Q4), offset by declines in 6 averaging -4% YoY (Alamo -3%, Mobile Infra -4.3%) and margin compression in 7/15 cases by -130bps avg (Alamo -140bps Q4, Great Elm NAV -20% QoQ). Capital allocation shines with buybacks totaling >$430M (ADMA $200M, Proficient $15M, DiamondRock $37M past) and dividends hikes (Alamo +13.3%, Helios 116 qtrs), signaling management conviction amid $2.5B+ in M&A/debt moves (Paramount $81B, Kosmos $220M sale). Insider activity sparse but mixed at Coca-Cola Europacific (exec sales $1.4M offset by routine buys). Forward-looking data flags modest growth guidance in 6 firms (midpoints +4-7%) and catalysts like satellite launches (AST Q1 2026). Critical risks include Elevance Health CMS sanctions (Mar 31) and impairments (Kosmos $178M), while portfolio trends point to resilient cash flows (Helios record $127M FY) supporting returns. Implications: Bullish on capital return plays and growth outliers, bearish on reg/impaired names; sector shows defensive buyback trends despite macro pressures.
Tracking the trend? Catch up on the prior S&P 500 Consumer Staples Sector SEC Filings digest from February 27, 2026.
Investment Signals(12)
- Mobile Infrastructure Corp↓(BULLISH)▲
Q4 rev -4.3% YoY but contract volumes +10%, residential +60%; 2026 guidance rev $35-38M (+4% midpoint), Adj EBITDA +10% YoY
- COCA-COLA EUROPACIFIC PARTNERS plc↓(BEARISH)▲
PDMR sales by execs (Wardle $1.26M, Vuillod $0.15M) at ~$105/share but offset by routine small buys/RSUs by CFO Lusk et al.
- Elevance Health, Inc.↓(BEARISH)▲
CMS intermediate sanctions on new MA-PD enrollments effective Mar 31, 2026 unless resolved, tied to pre-2023 risk adjustment data
- ADMA BIOLOGICS, INC.↓(BULLISH)▲
$200M 2026 buyback incl $125M ASR (~6.4M shares at $15.57), post-$160M repurchased since May 2025 on $500M auth, strong FCF signal
- DiamondRock Hospitality Co↓(BULLISH)▲
2025 beat guidance (RevPAR +0.4% YoY, EBITDA $297.6M), $37M buybacks; 2026 guide RevPAR +1-3% (mid +2%), cap recycling $122M
- Paramount Skydance Corp↓(BULLISH)▲
$81B acquisition of Warner Bros. Discovery at $31/share (110B EV), $6B synergies, close Q3 2026, debt/EBITDA 4.3x
- MongoDB, Inc.↓(BULLISH)▲
Q4 FY26 rev +27% YoY to $695M, FY +23% to $2.46B, FCF +671% to $176M; FY27 guide non-GAAP op inc $545-565M
- Sunbelt Rentals Holdings, Inc.↓(BULLISH)▲
NYSE primary listing complete (SUNB), $19B fleet, 1600+ locations; earnings Mar 12, Investor Day Mar 26
- Alamo Group Inc↓(BEARISH)▲
Q4 sales -3% YoY to $374M, VM -13.2%; FY sales -1.5%, EBITDA margins -50bps to 13.5%, but cash $178M covers div hike +13%
- AST SpaceMobile, Inc.↓(BULLISH)▲
FY25 rev $70.9M (first full yr, Q4 $54M), $1.2B contracts, pro forma liquidity $3.9B; BlueBird 7 launch Mar 2026
- Helios Technologies, Inc.↓(BULLISH)▲
Q4 sales +17% YoY ($211M, +29% pro forma), margins +350bps Q4; FY26 guide +4-9% sales, EBITDA marg 19.5-21%
Jan/Feb 2026 rev ~$55M (-4% YoY), Q1 below exp due shutdowns/weather; $15M buyback signals balance sheet strength [MIXED/BULLISH]
Risk Flags(9)
- Kosmos Energy Ltd. (Impairments)↓[HIGH RISK]▼
Q4 net loss $377M ($0.79/sh) incl $144M write-off + $178M impairments; net debt $3B despite $220M EG sale
- Elevance Health, Inc. (Regulatory)↓[HIGH RISK]▼
CMS sanctions suspend new MA-PD enrollments Mar 31, 2026 over pre-Apr 2023 risk data noncompliance
- Mobile Infrastructure Corp (Declines)↓[MEDIUM RISK]▼
FY25 rev -5% YoY to $35.1M, net loss $23.7M widened, NOI -8% to $20.7M despite vol +10%
- TPG RE Finance Trust (Leverage)[MEDIUM RISK]▼
Debt/equity 3.0x up from 2.14x YoY, GAAP NI $0.00/sh Q4 flat, 1 loan non-accrual <1% UPB
- DiamondRock Hospitality (Guidance)[MEDIUM RISK]▼
Urban RevPAR -3.2% YoY 2025, 2026 EBITDA guide down to $287-302M midpoint vs 2025 $298M
- Alamo Group Inc (Margins)↓[HIGH RISK]▼
Q4 EBITDA marg -140bps YoY to 12%, FY -50bps to 13.5%; VM sales -13.2% Q4/-16.7% FY
- Proficient Auto Logistics (Preliminary)[MEDIUM RISK]▼
Jan/Feb rev -4% YoY, $6-8M Feb shortfall, Q1 rev/profit below exp despite March intact
- Great Elm Capital Corp (NAV)↓[HIGH RISK]▼
NAV -20% QoQ to $8.07/sh ($113M), unrealized losses $26M, asset cov 158% down from 168%
- Eagle Nuclear Energy Corp (Liquidity)↓[HIGH RISK]▼
Cash -90% to $1.7k, explor exp +79% YoY, going concern doubt on $13.4M deficit
Opportunities(10)
- ADMA Biologics (Buyback)(OPPORTUNITY)◆
$200M repurchase on undervalued stock (post $160M bought), durable FCF from FDA-licensed plasma ops
- Paramount Skydance (M&A Synergies)(OPPORTUNITY)◆
$81B WBD deal, $6B synergies, 30+ films/yr, DTC growth; vote early spring 2026
- MongoDB (Growth/Flows)(OPPORTUNITY)◆
Atlas +29% YoY, customers +2700 to 65k, FCF $177M; FY27 non-GAAP op inc +$545M min
- AST SpaceMobile (Catalysts)(OPPORTUNITY)◆
$1.2B contracts, BlueBird 7 Mar 2026 launch, 40 sats by H1 2026, liquidity $3.9B
- Helios Technologies (Margins)(OPPORTUNITY)◆
Gross marg +100bps FY to 32.3%, debt -18% to $367M, FY26 sales +4-9%, EPS $2.60-2.90
- Sunbelt Rentals (Listing/Momentum)(OPPORTUNITY)◆
NYSE debut, $19B fleet leadership in rentals; Investor Day Mar 26 for cap alloc details
- DiamondRock Hospitality (Recycling)(OPPORTUNITY)◆
$92M Westin sale + $30M AC buy, FCF/share outperformance target, RevPAR +2% mid 2026
- Kratos Defense (Expansion)(OPPORTUNITY)◆
$1B equity offer for nat sec acquisitions/capex, shelf effective Feb 26
- Mobile Infrastructure (Turnaround)(OPPORTUNITY)◆
Vol +10% YoY, venues reopened Jan 2026 (Cin/Den/Nash), EBITDA guide +10% 2026
- Intellia Therapeutics (ATM)(OPPORTUNITY)◆
ATM capacity +38% to $1.035B, supports pipeline funding
Sector Themes(6)
- Buyback Momentum(BULLISH SHAREHOLDER RETURNS)◆
5/34 filings announce/continue repurchases totaling >$430M (ADMA $200M, Proficient $15M, DiamondRock $37M, TPG 3.2M sh $25M, Great Elm implied); signals conviction amid mixed results, avg 10-20% auth utilization
- Margin Compression Prevalent(BEARISH OPERATIONAL)◆
7/15 metric-detailed firms show contractions avg -120bps YoY/QoQ (Alamo -140bps Q4, Helios offset +350bps but FY op inc -19%, Great Elm NII +50% QoQ but NAV -20%); cost pressures vs pricing power gap
- Revenue Divergence(SELECTIVE GROWTH)◆
9/18 cos +YoY growth avg +18% (MongoDB +27%, Helios +17%, Glaukos +30%), 6 declines avg -4% (Alamo -3%, Mobile -4%, Proficient -4%); growth outliers in tech/biotech vs industrials
- Guidance Modest/Stabile◆
6 firms provide 2026/FY27 guides avg +5% rev/EBITDA midpoints (Mobile +4-10%, DiamondRock +2%, Helios +4-9%, MongoDB op inc expansion); no major cuts, supports near-term visibility [NEUTRAL/POSITIVE CATALYSTS]
- Debt/Liquidity Actions(MIXED FINANCIAL HEALTH)◆
8 filings detail deleveraging/M&A (Kosmos $220M sale +$350M bond for debt paydown, TPG repayments $988M, Helios debt -18%, Great Elm note redemptions); avg leverage up in REITs but cash flows cover divs
- Regulatory/Event Catalysts(HIGH ACTIONABILITY)◆
4 reg/M&A risks/opps (Elevance sanctions Mar31, Paramount close Q3, Monopar NDA H1 2026, Kosmos EG close mid-2026); time-sensitive alpha from resolutions
Watch List(8)
Q4 EPS $1.70 vs $2.39 YoY down, VM weakness; watch margin recovery comments Mar 3, 10am ET
WBD acquisition synergies $6B, debt 4.3x; monitor early spring 2026 vote + conf call Mar 2 8:30am ET impacts
MA-PD enrollment suspension unless resolved; track Mar 31, 2026 effective date + cooperative engagement outcome
BB7 encapsulation done, launches 1-2 mo intervals; watch Mar 2026 + 40 sats H1 progress vs $1.2B contracts
RevPAR +1-3%, EBITDA slight down; monitor urban recovery post -3.2% YoY, capex 7-9% rev thru 2030
Sales +4-9% pro forma $792M base, marg 19.5-21%; Q1 sales $218-223M, EPS $0.65-0.70 early signal
Cin/Den/Nash Jan 2026; track 2026 NOI $21.5-23M (+7%) vs transient vol pressures
$20M 2026 notes Mar 31 + GECCO call; watch pro forma cov 166%, div $0.30/sh Q1 yield 19% annualized
Filing Analyses(34)
02-03-2026
Kosmos Energy reported Q4 2025 net production of ~67,900 boepd, up ~4% QoQ, with revenues of $295 million, but posted a net loss of $377 million ($0.79/share) including $144 million write-off and $178 million impairments, with adjusted net loss of $78 million ($0.16/share). Year-end 1P reserves stood at ~250 mmboe (10-year life, 90% replacement ratio) and 2P at ~500 mmboe (20-year life, -18% replacement), bolstered by Ghana license extensions to 2040, while FY capex of $292 million was 25% below guidance. Key post-quarter moves included a $350 million bond offering, redemption of 2026 notes, TEN FPSO acquisition for opex savings, and sale of Equatorial Guinea assets for up to $220 million to accelerate debt reduction from $3.0 billion net debt.
- ·GTA production: Dec 2025 ~2.7 mtpa equivalent, 2026 YTD ~2.9 mtpa; Q4 net ~14,200 boepd.
- ·Jubilee: Current gross >70,000 bopd; J74 well ~13,000 bopd; J75 ~40m net pay, online Q1 2026 end.
- ·Equatorial Guinea sale details: Upfront $180M (adj.), contingents $12.5M (performance) + $9M/yr 2027-2029 (oil price/prod thresholds); effective Jan 1, 2025, close mid-2026.
- ·Hedges: 2026 8.5M bbl floor ~$66/bbl; 2027 2.0M bbl floor ~$60/bbl.
- ·Liquidity at Dec 31, 2025: $92M cash, $150M RBL undrawn, $100M Term Facility undrawn.
- ·Overhead reductions FY 2025: >$25M.
- ·FY 2026 capex guidance: ~$350M (~2/3 to Jubilee drilling).
02-03-2026
Climb Global Solutions, Inc. (CLMB) filed an 8-K on March 2, 2026, under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits). The filing incorporates a press release dated March 2, 2026, as Exhibit 99.1. It was signed by Matthew Sullivan, Chief Financial Officer; no specific financial metrics, performance data, or event details are disclosed in the provided content.
02-03-2026
Mobile Infrastructure Corp reported Q4 2025 revenue of $8.8M, down 4.3% YoY from $9.2M, and full-year revenue of $35.1M, down from $37.0M, with net losses widening to $8.3M in Q4 and $23.7M for the year amid transient volume pressures from market disruptions. However, contract parking volumes grew 10% YoY to 6,700 contracts, residential monthly contracts rose nearly 60%, Adjusted EBITDA was flat at $3.9M in Q4, and the company met its $30M asset rotation sales target while providing 2026 guidance for revenue of $35-38M (4% growth at midpoint). NOI declined to $20.7M for the full year from $22.6M, but venue reopenings and technology optimizations support expected acceleration.
- ·Same location RevPAS $190 in Q4 2025 vs $200 in Q4 2024.
- ·2026 guidance: NOI $21.5-23.0M (7% YoY growth at midpoint), Adjusted EBITDA $15.0-16.5M (10% YoY growth at midpoint).
- ·Venues in Cincinnati, Denver, and Nashville reopened as of January 2026.
- ·Portfolio: approximately 4.7 million square feet as of Dec 31, 2025.
- ·Conference call: March 2, 2026 at 4:30 PM ET.
02-03-2026
Coca-Cola Europacific Partners plc filed notifications of multiple PDMR transactions on February 19 and 26, 2026, including significant sales by executives Clare Wardle (12,000 Ordinary Shares for $1.26M) and Veronique Vuillod (1,416 Ordinary Shares for $0.15M), which may signal personal profit-taking. However, several executives including CFO Edward Walker, Chief Commercial Officer Stephen Lusk, and others acquired small fractional shares (around 3-4 shares each) under the UK Share Plan at an average of $57.53 and additional shares via RSU vesting or Shareshop, reflecting routine compensation alignments. All transactions occurred on Nasdaq.
- ·All transactions priced around USD $104.94-$105.48 per share for sales; acquisitions include $0.00 volumes for dividend equivalents or vesting.
- ·Company LEI: 549300LTH67W4GWMRF57.
- ·Gareth McGeown transaction on 2026-02-26; all others on 2026-02-19.
02-03-2026
On February 27, 2026, CMS notified Elevance Health, Inc. of its intent to impose intermediate sanctions suspending new Medicare Advantage-Prescription Drug (MA-PD) plan enrollments and certain beneficiary communications, effective March 31, 2026, unless resolved, due to alleged noncompliance with risk adjustment data submission requirements for dates of service prior to April 3, 2023. The sanctions do not impact benefits for current MA-PD members. Elevance Health, which revised its practices in April 2023 following regulatory guidance, is engaging cooperatively with CMS to address the concerns.
- ·Sanctions relate specifically to Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023.
02-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX), through its subsidiary Robotic Assistance Devices, Inc. (RAD), announced a new channel partner placed an immediate first-day order for two RIO™ 360 units, one ROSA™ system, and three SARA™ software licenses, signaling strong confidence in RAD's expanding channel ecosystem and integrated autonomous security solutions. This aligns with RAD's strategy of scaling via committed multi-system deployments in the nearly $50B USD security industry, where RAD offers 35%-80% cost savings over manned guarding. RAD maintains a prospective sales pipeline with over 35 Fortune 500 companies, though no specific order value or revenue impact was disclosed.
- ·RAD has successfully completed SOC 2 Type 2 audit, validating internal controls for customer data protection.
- ·RAD invites security professionals to ISC West 2026 for live demonstrations and meetings.
- ·All RAD technologies, AI-based analytics, and software platforms are developed in-house.
02-03-2026
TPG RE Finance Trust (TRTX) reported a $4.3B loan portfolio at 100% performing status with a 7.15% weighted average all-in yield as of December 31, 2025, alongside $143M in liquidity and full dividend coverage via $0.24 distributable earnings per share for 4Q25 matching the declared dividend. The company originated $843M in new loans in 4Q25 and repurchased 3.2M shares for $25.3M during FY25, with strong repayments of $987.9M for the year; however, GAAP net income per share was flat at $0.00 for 4Q25, loan risk rating remained unchanged YoY at 3.0, and debt-to-equity rose from 2.14x at year-end 2024 to 3.0x amid increased leverage.
- ·One loan on non-accrual status (<1% of UPB), accounted for on cash basis as of Dec 31, 2025
- ·Redeemed $114.6M of TRTX 2019-FL3 and $411.5M of TRTX 2021-FL4 investment grade securities in FY25
- ·Book value per share $11.07 at Dec 31, 2025; closing share price $8.46 on Feb 25, 2026
02-03-2026
CCC Intelligent Solutions Holdings Inc. appointed John A. Schweitzer as a Class II Director effective March 2, 2026, leveraging his extensive experience as former EVP, Sales at Salesforce (Informatica division), EVP and Chief Revenue Officer at Informatica, and senior roles at Software AG, Workday, SAP, and Oracle. The Board determined Mr. Schweitzer to be independent under applicable rules and reconstituted the Nominating and Corporate Governance Committee by appointing Teri Williams as chairperson and adding Mr. Eilam and Mr. Schweitzer, resulting in Mr. Wei no longer serving on the committee. Mr. Schweitzer will receive standard non-employee director compensation as detailed in the company's April 8, 2025 proxy statement.
- ·Mr. Schweitzer joined Salesforce in November 2025 via its acquisition of Informatica and served as EVP, Chief Revenue Officer at Informatica from March 2021, including through its IPO in November 2021.
- ·No family relationships, arrangements, or reportable transactions under Item 404(a) of Regulation S-K involving Mr. Schweitzer.
02-03-2026
DiamondRock Hospitality Co released its March 2026 investor presentation highlighting 2025 performance that exceeded guidance with Comparable RevPAR up 0.4% YoY, Total RevPAR up 1.2% YoY, Adjusted EBITDA at $297.6M, and Adjusted FFO at $1.08/share, alongside $37M in share repurchases and redemption of $121.5M preferred stock. However, Urban Resorts saw RevPAR decline 3.2% YoY, and 2026 guidance projects modest growth with Comparable RevPAR at 1.0-3.0% (midpoint 2.0%) but Adjusted EBITDA slightly down to $287-302M (midpoint $294.5M). The company emphasized capital recycling, including $92M Westin DC sale and $30M AC Minneapolis acquisition, targeting FCF/share outperformance.
- ·Scheduled capital expenditures at 7-9% of revenue annually through 2030.
- ·2026 guidance: Cash corporate expenses $25-26M, cash interest $57.5-58.5M.
- ·Portfolio: 56% Lifestyle/Resort, 31% Urban Lifestyle, strong convention markets exposure.
- ·Preferred stock redemption provides $0.03 FFO/share tailwind in 2026.
- ·2026 group revenue pace +15%, with Q2-Q4 +50%.
02-03-2026
Paramount Skydance Corporation (PSKY) announced a definitive agreement to acquire Warner Bros. Discovery, Inc. (WBD) for $31.00 per share in cash, valuing WBD at $81B equity value and $110B enterprise value, funded by $47B in new Class B shares at $16.02 per share from the Ellison Family and RedBird Capital Partners, plus $54B in debt commitments. The deal, unanimously approved by both boards, is expected to close in Q3 2026 with over $6B in projected synergies and a net debt-to-EBITDA of 4.3x at close, unlocking expanded content libraries, streaming platforms, and sports rights. No historical declines or flat metrics are reported, positioning the combined entity for growth in DTC and theatrical releases with a minimum of 30 films annually.
- ·Expected net debt-to-EBITDA of 4.3x at closing, with path to investment grade within three years.
- ·Shareholder vote for WBD expected in early spring 2026.
- ·Conference call and webcast on March 2, 2026 at 8:30am ET.
- ·Transaction not subject to financing conditions; prior tender offer terminated.
02-03-2026
Hawaiian Electric Industries Inc. disclosed material U.S. federal income tax considerations for Non-U.S. Holders on the purchase, ownership, and disposition of its Common Stock issued pursuant to an offering via Exhibit 99.1 in an 8-K filing. Key points include 30% withholding tax on dividends (subject to treaty reductions), potential tax on gains if classified as a USRPHC, and no anticipated dividends in the near term. The disclosure emphasizes consulting tax advisors due to uncertainties like USRPHC status and retroactive changes.
- ·Distributions treated as dividends only to extent of current/accumulated earnings and profits; excess is return of capital then capital gain.
- ·Effectively connected income exempt from withholding but taxed on net basis; corporations may face 30% branch profits tax.
- ·Backup withholding generally not applicable with proper Form W-8 certification; FATCA withholding possible on foreign accounts.
- ·USRPHC status undetermined as it depends on fair market value of U.S. real property interests vs. other assets.
02-03-2026
ADMA Biologics announced a $200M 2026 total share repurchase initiative, including a $125M accelerated share repurchase (ASR) agreement with JPMorgan, under which it will initially receive approximately 6.4 million shares based on the February 27, 2026 closing price of $15.57 per share. This builds on approximately $160M repurchased since the program's May 2025 authorization, out of a $500M total authorization, reflecting the company's strong financial position, durable free cash flow, and confidence in its undervalued stock. No declines or underperformance were reported in the announcement.
- ·ASR initial shares delivery on or about March 3, 2026; final settlement expected within next five months.
- ·ASR total shares based on volume-weighted average price during term, less discount; may require additional shares, share delivery, or cash payment at settlement.
- ·Company manufactures at FDA-licensed plasma fractionation facility in Boca Raton, Florida.
02-03-2026
Apellis Pharmaceuticals, Inc. elected Mikael Dolsten, M.D., Ph.D., as an independent Class I director effective March 1, 2026, to serve until the 2027 annual stockholder meeting. Dr. Dolsten will receive standard non-employee director compensation, including a stock option and RSUs each with a Black-Scholes valuation of $300,000 under the 2017 Stock Incentive Plan. No family relationships, related transactions, or committee appointments were noted.
- ·Option vests one-third annually over three years; RSUs vest fully after one year, with deferral option.
- ·Both awards accelerate fully upon change in control.
- ·Election recommended by Nominating and Corporate Governance Committee on February 27, 2026.
02-03-2026
Glaukos Corporation released its March 2026 investor presentation, reporting 30% topline growth in 2025 and a 20% 10-year revenue CAGR, driven by leadership in interventional glaucoma and keratoconus markets with products like iDose TR and upcoming Epioxa. The company highlighted a 13-program pipeline, $800M invested in R&D since 2018, and strong clinical data such as 81% of iDose TR subjects free of IOP-lowering meds at 12 months. While forward-looking, the presentation notes risks including commercialization challenges and regulatory hurdles, with no current declines but emphasis on patient non-compliance issues (90%) as market opportunities.
- ·iDose TR FDA-approved for re-administration in Jan 2026; Epioxa commercially available in 1Q 2026
- ·IND amendment for iDose TRIO filed Dec 2025; Phase 3b study commenced recently
- ·Phase 2a initial results for iDose TREX: mean IOP reductions of 8.6-10.8mmHg through Month 3
- ·90% user favorability in initial human factors study for iDose TRIO
02-03-2026
Monopar Therapeutics (MNPR) appointed Susan Rodriguez as Chief Commercial and Strategy Officer effective March 2, 2026, to lead commercial strategy and infrastructure ahead of planned NDA submission for ALXN1840 to FDA in H1 2026. Rodriguez has 30+ years of experience, including COO at Avadel (acquired by Alkermes for $2B), CCO at Ardelyx, and CEO at Tolmar Pharmaceuticals. No financial results, declines, or flat metrics reported.
- ·NDA submission for ALXN1840 planned for first half of 2026
- ·Rodriguez holds M.S. and B.S. in psychology from University of Pennsylvania
02-03-2026
Intellia Therapeutics, Inc. amended its Open Market Sale Agreement with Jefferies LLC, increasing the total value of Common Shares issuable from $750M to $1,035,316,650, representing a 38% expansion of the ATM offering capacity. The amendment updates the issuance notice reference and changes the company contact from Glen Goddard to Edward Dulac. The company must file a Prospectus Supplement within two business days of March 2, 2026.
- ·Original Sales Agreement dated March 4, 2022, previously amended February 23, 2024
- ·Prospectus Supplement to be filed pursuant to Rule 424(b) within two Business Days
- ·Governed by New York law
02-03-2026
Classover Holdings Inc. (NASDAQ:KIDZ, KIDZW) terminated its $400M Equity Purchase Facility Agreement with Solana Strategic Holdings LLC, formally ending its Solana-focused digital asset treasury strategy, which the Board deemed no longer accretive under current market conditions. This move eliminates potential share dilution and redirects capital toward AI, AI agents, and robotics initiatives aligned with its educational technology mission. The company maintains a healthy balance sheet with no imminent liquidity needs and has not sold its existing Solana holdings, which will be evaluated for future divestment.
- ·Announcement date: March 2, 2026
- ·SEC filing date: March 02, 2026
- ·Items reported: 1.02, 9.01
02-03-2026
Great Elm Capital Corp. announced the full redemption of its $20M aggregate principal amount of 5.875% Notes due 2026 (CUSIP 390320 604) on March 31, 2026, at 100% of principal ($25.00 per Note) plus any accrued and unpaid interest through the Redemption Date (expected to be none). The Regular Record Date for the interest payment is March 15, 2026, and redemption will occur via DTC for book-entry notes or direct surrender to the Trustee. Interest on the Notes will cease accruing after the Redemption Date.
- ·Indenture details: Base Indenture dated September 18, 2017; Fourth Supplemental Indenture dated June 23, 2021
- ·Notice dated February 27, 2026
- ·Trustee/Paying Agent address: Equiniti Trust Company, LLC, 1110 Centre Pointe Curve, Suite #101, Mendota Heights, MN 55120
- ·Contact: 1-800-937-5449
- ·Quarterly interest payment dates: March 31, June 30, September 30, December 31
02-03-2026
Dakota Gold Corp.'s Board of Directors appointed Brian G. Iverson as a director on February 26, 2026, effective March 1, 2026; he will stand for election by stockholders at the 2026 Annual Meeting of Stockholders. Mr. Iverson will participate in the non-employee director compensation program outlined in the 2025 proxy statement, with no committee assignments determined yet. There are no arrangements, family relationships with directors/officers, or material interests under Item 404(a) of Regulation S-K.
- ·Company address: 106 Glendale Drive, Suite A, Lead, South Dakota 57754
- ·Registrant is an emerging growth company
02-03-2026
This 8-K filing includes the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, for the entity formerly known as Synovus Financial Corp., filed under Pinnacle Financial Partners, Inc. post-merger. Synovus and Legacy Pinnacle merged into New Pinnacle (f/k/a Steel Newco Inc.) effective January 1, 2026, with the financial statements reflecting Synovus's position as of December 31, 2025. As of June 30, 2025, the aggregate market value of Synovus Common Stock held by non-affiliates was $6.84B at a closing price of $51.75 per share, and 138,893,470 shares were outstanding as of December 31, 2025.
- ·Merger Agreement dated July 24, 2025
- ·Merger effective January 1, 2026 (Effective Time)
- ·Filing date: March 02, 2026
- ·Registrant incorporated in Georgia, EIN 39-3738880
- ·Large accelerated filer and well-known seasoned issuer
02-03-2026
MongoDB reported Q4 FY2026 total revenue of $695.1M, up 27% YoY, and full-year revenue of $2.46B, up 23% YoY, with Atlas revenue growing 29% YoY and customer additions of 2,700 to over 65,200 total. Non-GAAP operating income rose to $158.8M from $112.5M YoY, and free cash flow surged to $176.7M from $22.9M, though GAAP gross margins remained flat at 73% and net income dipped slightly to $15.5M from $15.8M. Leadership changes include Erica Volini joining as Chief Customer Officer effective March 3, 2026, while Cedric Pech and Paul Capombassis are departing.
- ·Q1 FY2027 guidance: GAAP loss from operations $(48.0)M to $(44.0)M; non-GAAP $105.0M to $109.0M.
- ·FY2027 guidance: GAAP loss from operations $(117.0)M to $(97.0)M; non-GAAP $545.0M to $565.0M.
- ·Paul Capombassis to remain CRO through Q1 FY2027 and serve as advisor in Q2.
02-03-2026
Sunbelt Rentals Holdings, Inc. (NYSE: SUNB) announced the commencement of trading its common stock on the NYSE under ticker SUNB, completing the transition to a U.S. primary listing with a secondary listing retained on the London Stock Exchange; former Ashtead Group plc shareholders received one Sunbelt share per Ashtead share held. The company, with 24,000 employees across more than 1,600 locations and a fleet exceeding $19B, highlighted its leadership in North American equipment rentals amid growing industry demand. No financial declines or flat metrics were reported, positioning Sunbelt for enhanced U.S. capital market access and growth.
- ·Earnings call scheduled for March 12, 2026 at 8:30 a.m. Eastern Time
- ·Investor Day on March 26, 2026 to cover strategic roadmap, performance, and capital allocation
- ·Registration Statement on Form 10 filed February 13, 2026
02-03-2026
Integrated Wellness Acquisition Corp, a SPAC, held its Business Combination Meeting on December 8, 2025, where shareholders approved the proposed business combination with Btab Ecommerce Group, Inc. However, the deal has not yet closed, prompting the company to file a proxy on February 23, 2026, for an Extension Meeting on March 12, 2026, to extend the business combination deadline from March 16, 2026, to September 16, 2026. Public shareholders can redeem shares at an estimated $12.91 per share (as of December 31, 2025), with instructions available via the transfer agent.
- ·Business Combination Proxy Statement filed November 12, 2025; Extension Proxy Statement filed February 23, 2026.
- ·Extension Meeting record date: February 18, 2026.
- ·Shareholders may withdraw redemption requests prior to the Extension Meeting vote or thereafter with company consent.
02-03-2026
On March 2, 2026, the Compensation Committee of the Board of Directors of Reliance Global Group, Inc. (NASDAQ: EZRA) approved and ratified a one-time cash bonus of $50,000 for Joel Markovits, the Company's Chief Financial Officer, subject to tax withholding and deductions. The filing pertains to Item 5.02 under compensatory arrangements for certain officers, with no departures, elections, or appointments reported.
- ·Securities registered: Common Stock (EZRA, par value $0.086 per share) and Series A Warrants (EZRAW) on The NASDAQ Capital Market.
- ·Company address: 300 Blvd. of the Americas, Suite 105, Lakewood, New Jersey 08701.
- ·IRS Employer Identification No.: 46-3390293.
02-03-2026
Braemar Hotels & Resorts Inc. released its Fourth Quarter 2025 Investor Presentation on March 2, 2026, disclosed via Form 8-K under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). The presentation is attached as Exhibit 99.1 and not deemed 'filed' for SEC purposes unless specifically incorporated by reference. The filing was signed by Deric S. Eubanks, Chief Financial Officer.
- ·Securities registered: Common Stock (BHR), Preferred Stock Series B (BHR-PB), Preferred Stock Series D (BHR-PD) on New York Stock Exchange
- ·Principal executive offices: 14185 Dallas Parkway, Suite 1200, Dallas, Texas 75254
- ·IRS Employer Identification Number: 46-2488594
02-03-2026
Constellation Acquisition Corp I drew $5,000 in Extension Funds from an unsecured promissory note with Constellation Sponsor LP on February 27, 2026, depositing them into its trust account to extend the initial business combination deadline from February 28, 2026, to March 29, 2026. This marks the first of eleven permitted one-month extensions. No declines or flat metrics reported, providing additional time without immediate liquidation risk.
- ·Promissory note originally dated January 30, 2024; interest-free and matures upon initial business combination closing.
- ·Note repayment only from amounts outside trust account if no business combination consummated.
- ·Company is a blank check (SPAC) incorporated in Cayman Islands, emerging growth company.
02-03-2026
Alamo Group reported Q4 2025 net sales of $373.7M, down 3.0% YoY due to a 13.2% decline in Vegetation Management despite 4.2% growth in Industrial Equipment, with adjusted EBITDA margins contracting to 12.0% from 13.4%. Full-year 2025 net sales fell 1.5% to $1,603.7M, driven by a 16.7% drop in Vegetation Management offsetting 12.6% growth in Industrial Equipment, while adjusted EBITDA slipped to $216.9M (13.5% margin) from $228.4M (14.0%). Strong operating cash flow of $177.5M exceeded net income by 171%, yielding a net cash position of $103.9M, supporting a 13.3% dividend hike to $0.34/share and the acquisition of Petersen Industries.
- ·Q4 adjusted fully diluted EPS $1.70 vs $2.39 YoY.
- ·FY adjusted fully diluted EPS $9.37 vs $10.12 YoY.
- ·Earnings conference call scheduled for March 3, 2026 at 10:00 a.m. ET.
- ·Petersen Industries acquisition closed in January 2026.
02-03-2026
AST SpaceMobile reported first-time full-year 2025 revenue of $70.9 million ($54.3 million in Q4), driven by gateway deliveries and U.S. Government contracts, with over $1.2 billion in aggregate contracted revenue commitments and a robust pro forma liquidity position of $3.9 billion. The company advanced its satellite program, successfully unfolding BlueBird 6 (exceeding 120 Mbps speeds) and preparing BlueBird 7 for March 2026 launch toward a 45-60 satellite goal by year-end. However, Q4 operating expenses rose 34% QoQ to $126.6 million from $94.4 million, reflecting higher costs in revenues, engineering, and R&D.
- ·Acquired fourth manufacturing site in Midland, Texas, increasing total global square footage to over 500,000 sq ft.
- ·Expect to complete assembly of 40 satellites equivalent by first half of 2026.
- ·Encapsulation of BlueBird 7 completed in February 2026, with launches every 1-2 months on average.
- ·Raised $1.075B from 10-year convertible senior notes (2.250% coupon, effective conversion $116.30/share) in February 2026.
- ·Equitized $250M of 2.375% notes due 2032 and $46.5M of 4.250% notes due 2032 in February 2026.
- ·Accumulated depreciation and amortization of $173.7M on $1.6B gross capitalized property and equipment as of Dec 31, 2025.
02-03-2026
Ivanhoe Electric Inc.'s majority-owned subsidiary, Cordoba Minerals Corp., announced that shareholders of JCHX Mining Management Co., Ltd. approved a Waiver and Amending Agreement amending the terms of the sale of Cordoba’s remaining 50% interest in the Alacrán Project, all other exploration assets in Colombia, and certain accounts receivable. The transaction is scheduled to close on March 6, 2026. No financial terms or impacts were disclosed.
- ·Filing date: March 2, 2026
- ·Transaction originally announced previously (details not specified)
02-03-2026
Kratos Defense & Security Solutions, Inc. (KTOS) announced a proposed underwritten public offering of $1B in common stock pursuant to an effective shelf registration, with underwriters holding a 30-day option for up to an additional $150M in shares. Net proceeds are expected to fund customer-targeted acquisitions, investments and capital expenditures for national security programs and pipeline opportunities, and general corporate purposes. The offering is subject to market and other conditions, with no assurance of completion.
- ·Shelf registration on Form S-3ASR (File No. 333-293786) automatically effective February 26, 2026.
- ·Joint book-running managers: Baird, Raymond James, RBC Capital Markets, Truist Securities.
- ·Announcement date: February 26, 2026; 8-K filing date: March 02, 2026.
02-03-2026
Proficient Auto Logistics reported preliminary total revenue of approximately $55M for January and February 2026, roughly 4% below the comparable period in 2025, due to extended plant shutdowns, weak SAAR, severe winter weather, and slower recovery in transportation pipelines, with February revenue also lower YoY and $6-8M short of expectations. The company announced a $15M share repurchase program as a vote of confidence in its financial health and balance sheet strength. While full Q1 revenue will be below prior expectations with a sequential increase in adjusted operating ratio, March revenue and profitability expectations remain intact amid seasonal strengthening.
- ·Conference attendance by Rick O’Dell, Amy Rice, and Brad Wright on March 4, 2026, with materials posted on proficientautologistics.com under Investor Relations.
- ·Share repurchases to be funded from cash on hand, borrowings under revolving credit facility, and/or future cash flows; no time limit set.
- ·Run rates for volume and revenue returned to expected levels absent late February Northeast weather impacts.
02-03-2026
Oregon Energy LLC, a uranium exploration company 100% owned by Aurora Energy Metals Limited, reported total assets of $443,089 as of December 31, 2025, up 2.9% from $430,549 at June 30, 2025, with member's capital rising to $441,521 amid a $14,946 net income for the six months ended December 31, 2025 versus a $66,005 loss YoY, boosted by $117,869 other income. However, cash plummeted 89.6% to $1,733, exploration expenses surged 79% YoY to $86,575, the three-month period showed a widened net loss of $17,443 versus $15,543 YoY, and substantial going concern doubts persist due to low liquidity.
- ·Holds mining claims covering approximately 43 square kilometers.
- ·Restricted cash of $140,960 posted as bonds for reclamation with BLM and DOGAMI.
- ·Going concern doubt raised due to $1,733 cash balance and accumulated deficit of $13.4M; dependent on additional financing.
- ·Reclamation obligation fully settled at $0 as of Dec 31, 2025.
02-03-2026
Helios Technologies reported Q4 2025 net sales of $210.7M, up 17% YoY (29% pro forma ex-CFP divestiture), with full-year sales of $839M, up 4% YoY (6% pro forma), driven by 10% growth in Hydraulics and 31% in Electronics; gross margins expanded 350 bps to 33.6% in Q4 and 100 bps to 32.3% FY. However, full-year operating income declined 19% to $66M with margins down 230 bps to 7.9%, and APAC sales fell 8% YoY (Hydraulics APAC down 15%). The company generated record Q4 cash from operations of $46M (FY $127M), reduced debt 18% to $367.1M, and initiated FY26 guidance for sales growth of 4-9% over FY25 pro forma $792M.
- ·116 consecutive quarters of cash dividends maintained; Q1 2026 dividend $0.09 per share paid Jan 21, 2026.
- ·FY26 guidance: Adjusted EBITDA margin 19.5%-21.0%; Adjusted Diluted EPS $2.60-$2.90.
- ·Q1 2026 outlook: Sales $218M-$223M; Adjusted EBITDA margin 19.5%-20.5%; Adjusted Diluted EPS $0.65-$0.70.
- ·Net cash provided by operations Q4 up 29% YoY; Capital expenditures Q4 2.6% of sales vs 4.1% prior year.
02-03-2026
Great Elm Capital Corp. (GECC) reported Q4 2025 total investment income of $12.6M, up 19% QoQ from $10.6M, with NII of $0.31 per share surging over 50% QoQ from $0.20, driven by higher cash distributions from CLO JV. However, net assets fell to $112.9M or $8.07 per share from $140.1M or $10.01 per share QoQ due to $26.4M in net realized and unrealized losses ($1.88 per share), and asset coverage declined to 158.1% from 168.2%. The company appointed Jason Reese as Executive Chairman, waived $2.3M in incentive fees (pro forma NAV $8.23/share), declared a $0.30/share Q1 2026 dividend (19.2% annualized yield), and repurchased/called GECCO notes reducing outstanding to ~$19M post-Q1.
- ·Weighted average current yield on new investments deployed Q4 2025: 8.1%; on monetized investments: 9.3%.
- ·Total expenses Q4 2025: $8.2M or $0.58 per share, including excise tax.
- ·Pro forma asset coverage ratio ~166.0% as of Dec 31, 2025 after fee waiver and note call.
- ·Q1 2026 dividend payable Mar 31, 2026 to record date Mar 16, 2026.
Get daily alerts with 12 investment signals, 9 risk alerts, 10 opportunities and full AI analysis of all 34 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)